ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
MK-7902-013: An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies
Protocol ID
MK-7902-013
Condition/s
Solid tumours
Diagnosis Stage
Relapsed/refractory
Sponsor
Merck Sharp & Dohme Corp.
Collaborators
Eisai Inc.
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 2
Age Eligibility
2 Years to 21 Years
International registry ID's
NCT04447755
Back to Registry
Study Title MK-7902-013: An Open-Label Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children Adolescents and Young Adults with Relapsed or Refractory Solid Malignancies
Protocol ID MK-7902-013
Disease (Sub Disease) Solid tumours
Diagnosis Stage Relapsed/refractory
Sponsor Merck Sharp & Dohme Corp.
Collaborators Eisai Inc.
Links https://clinicaltrials.gov/ct2/show/NCT04447755
Trial Status Closed to Recruitment
Trial Open Date 30/07/2020
Study Type Treatment
Phase Phase 2
Age Eligibility 2 Years to 21 Years
International registry ID's NCT04447755

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168